

@article {936,
	title = {Molecular and biological characterization of the 5 human-bovine rotavirus {(WC3)-based} reassortant strains of the pentavalent rotavirus vaccine, {RotaTeq.}},
	journal = {Virology},
	volume = {403},
	number = {2},
	year = {2010},
	pages = {111-127},
	abstract = {{RotaTeq} is a pentavalent rotavirus vaccine that contains five human-bovine reassortant strains (designated G1, G2, G3, G4, and P1) on the backbone of the naturally attenuated tissue culture-adapted parental bovine rotavirus {(BRV)} strain {WC3.} The viral genomes of each of the reassortant strains were completely sequenced and compared pairwise and phylogenetically among each other and to human rotavirus {(HRV)} and {BRV} reference strains. Reassortants G1, G2, G3, and G4 contained the {VP7} gene from their corresponding {HRV} parent strains, while reassortants G1 and G2 also contained the {VP3} gene (genotype M1) from the {HRV} parent strain. The P1 reassortant contained the {VP4} gene from the {HRV} parent strain and all the other gene segments from the {BRV} {WC3} strain. The human {VP7s} had a high level of overall amino acid identity {(G1:} 95-99\%, G2: 94-99\% G3: 96-100\%, G4: 93-99\%) when compared to those of representative rotavirus strains of their corresponding G serotypes. The {VP4} of the P1 reassortant had a high identity (92-97\%) with those of serotype {P1A[8]} {HRV} reference strains, while the {BRV} {VP7} showed identities ranging from 91\% to 94\% to those of serotype G6 {HRV} strains. Sequence analyses of the {BRV} or {HRV} genes confirmed that the fundamental structure of the proteins in the vaccine was similar to those of the {HRV} and {BRV} references strains. Sequences analyses showed that {RotaTeq} exhibited a high degree of genetic stability as no mutations were identified in the material of each reassortant, which undergoes two rounds of replication cycles in cell culture during the manufacturing process, when compared to the final material used to fill the dosing tubes. The infectivity of each of the reassortant strains of {RotaTeq,} like {HRV} strains, did not require the presence of sialic acid residues on the cell surface. The molecular and biologic characterization of {RotaTeq} adds to the significant body of clinical data supporting the consistent efficacy, immunogenicity, and safety of {RotaTeq.}},
	doi = {10.1016/j.virol.2010.04.004},
	url = {http://dx.doi.org/10.1016/j.virol.2010.04.004},
	author = {Matthijnssens, Jelle and Joelsson, Daniel B and Warakomski, Donald J and Zhou, Tingyi and Mathis, Pamela K and van Maanen, Marc-Henri H and Ranheim, Todd S and Ciarlet, Max}
}
